AstraZeneca may have provided an incomplete view of the efficacy data related to its COVID-19 vaccine clinical trial, according to the National Institute of Allergy and Infectious Diseases (NIAID) on Tuesday.
Facebooktwitterredditpinterestlinkedintumblrmail
rss